Skip to content
Search

Latest Stories

Mallya’s Force India to launch F1 car at Silverstone

Force India will be one of the first teams to show off their 2017 Formula One car after announcing a Feb. 22 launch at their Silverstone home base.

The Mercedes-powered team, who have a changed driver lineup with 20-year-old Frenchman Esteban Ocon joining Mexican Sergio Perez in place of Germany’s Nico Hulkenberg, finished a best ever fourth overall last year.


The team rolled out their 2016 car in Barcelona last February, before principal Vijay Mallya had his Indian diplomatic passport revoked in April with a judge in Mumbai issuing a non-bailable warrant for his arrest.

Indian authorities trying to recover about $1.4 billion from his collapsed Kingfisher Airlines want to question Mallya, who last March flew to Britain where he has an indefinite right of residency.

Mallya attended only one race in 2016, the British Grand Prix at the circuit across the road from the team’s Silverstone factory, and watched the rest remotely.

World champions Mercedes will launch their new car at Silverstone on Feb. 23, with Ferrari next out on the 24th in Italy.

Pre-season testing starts in Barcelona on Feb. 27 with other teams expected to present their cars at the Circuit de Catalunya on the opening day.

Teams usually leave launches as late as possible, unless they are just to show off a new livery on an old car, to give themselves as much time as they can to finalise new developments.

They will want to start testing with the new cars, however, because 2017 sees new rules with bigger tyres and changed aerodynamics that could shake up the pecking order.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less